Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apomorphine hydrochloride
Drug ID BADD_D00153
Description Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Indications and Usage Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.[L13919,L13922]
Marketing Status approved; investigational
ATC Code N04BC07; G04BE07
DrugBank ID DB00714
KEGG ID D02004
MeSH ID D001058
PubChem ID 9410
TTD Drug ID D0H6QU
NDC Product Code 38779-3276; 52465-105; 38779-1764; 52465-104; 51927-2303; 62991-1513; 52817-720; 12707-031; 49452-0700; 27505-004
UNII F39049Y068
Synonyms Apomorphine | Apomorphine Hydrochloride, Anhydrous | Apomorphine Hydrochloride Anhydrous | Apomorphine Hydrochloride | Apomorphin-Teclapharm | Apomorphin Teclapharm | Apomorphine Hydrochloride, Hemihydrate | Apokinon | Apomorphine Chloride | Britaject
Chemical Information
Molecular Formula C17H18ClNO2
CAS Registry Number 314-19-2
SMILES CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Cardiac failure congestive02.05.01.002--Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chorea17.01.01.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Dehydration14.05.05.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Fall12.01.08.002--
Fatigue08.01.01.002--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Libido increased21.03.02.007; 19.08.03.002--
Nausea07.01.07.001--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain in extremity15.03.04.010--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages